187 457

Cited 0 times in

The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout

DC Field Value Language
dc.contributor.author이수곤-
dc.date.accessioned2014-12-18T10:00:02Z-
dc.date.available2014-12-18T10:00:02Z-
dc.date.issued2013-
dc.identifier.issn2093-940X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/89228-
dc.description.abstractObjective: To compare the urate-lowering efficacy and the safety of febuxostat, allopurinol and placebo in Korean patients with gout for 4 weeks. Methods: Subjects (n=182) with gout were randomized to febuxostat (40, 80, 120 mg), allopurinol 300 mg, or placebo group. The primary end point was the proportion of subjects whose serum urate concentration fell to less than 6.0 mg/dL after the 4-week treatment. Results: The primary end point was reached at 25.7%, 80.0% and 83.3% of patients receiving 40, 80 and 120 mg of febuxostat, respectively, 58.3% of those receiving 300 mg of allopurinol and none of the placebo (p<0.001: each febuxostat dose or allopurinol group versus placebo group, p=0.0484 and p=0.0196: febuxostat 80 and 120 mg compared with allopurinol, respectively). The number and proportion of subjects who developed adverse events (AEs) were 13 subjects (37%), 14 (39%) and 18 (50%) in the febuxostat of 40, 80 and 120 mg group, respectively, 21 (57%) in the allopurinol 300 mg group and 17 (46%) in the placebo group. No statistically significant differences in the incidence rates of adverse events were observed between the groups. There was no significant difference in gout flare-up incidence. Conclusion: Febuxostat, 80 mg or 120 mg, was more effective than allopurinol (300 mg) or placebo, when lowering the serum urate. The safety of febuxostat and allopurinol was comparable.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.relation.isPartOfJournal of Rheumatic Diseases-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleThe Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSung Hwan Park-
dc.contributor.googleauthorYeong Wook Song-
dc.contributor.googleauthorWon Park-
dc.contributor.googleauthorEun Mi Koh-
dc.contributor.googleauthorBin Yoo-
dc.contributor.googleauthorSoo Kon Lee-
dc.contributor.googleauthorDae Hyun Yoo-
dc.contributor.googleauthorYun Jong Lee-
dc.contributor.googleauthorHyun Ah Kim-
dc.contributor.googleauthorHyo Jin Choi-
dc.contributor.googleauthorHo Youn Kim-
dc.contributor.googleauthorHyong Gi Jung-
dc.identifier.doi10.4078/jrd.2013.20.4.223-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02889-
dc.relation.journalcodeJ01737-
dc.identifier.pmidGout ; Febuxostat ; Urate-lowering efficacy ; Korean patients-
dc.subject.keywordGout-
dc.subject.keywordFebuxostat-
dc.subject.keywordUrate-lowering efficacy-
dc.subject.keywordKorean patients-
dc.contributor.alternativeNameLee, Soo Kon-
dc.contributor.affiliatedAuthorLee, Soo Kon-
dc.rights.accessRightsfree-
dc.citation.volume20-
dc.citation.number4-
dc.citation.startPage223-
dc.citation.endPage230-
dc.identifier.bibliographicCitationJournal of Rheumatic Diseases, Vol.20(4) : 223-230, 2013-
dc.identifier.rimsid34466-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.